Is There More Upside Ahead For CureVac N.V (NASDAQ: CVAC)

CureVac N.V (CVAC) concluded trading on Thursday at a closing price of $5.60, with 22.91 million shares of worth about $128.27 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 66.17% during that period and on June 12, 2025 the price saw a gain of about 37.59%. Currently the company’s common shares owned by public are about 225.16M shares, out of which, 93.99M shares are available for trading.

Stock saw a price change of 25.56% in past 5 days and over the past one month there was a price change of 64.95%. Year-to-date (YTD), CVAC shares are showing a performance of 64.22% which increased to 22.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.37 but also hit the highest price of $5.00 during that period. The average intraday trading volume for CureVac N.V shares is 652.55K. The stock is currently trading 29.64% above its 20-day simple moving average (SMA20), while that difference is up 52.82% for SMA50 and it goes to 70.45% higher than SMA200.

CureVac N.V (NASDAQ: CVAC) currently have 225.16M outstanding shares and institutions hold larger chunk of about 3.57% of that.

The stock has a current market capitalization of $1.26B and its 3Y-monthly beta is at 2.49. PE ratio of stock for trailing 12 months is 6.21, while it has posted earnings per share of $0.90 in the same period. It has Quick Ratio of 7.65 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CVAC, volatility over the week remained 17.55% while standing at 8.51% over the month.

Analysts are in expectations that CureVac N.V (CVAC) stock would likely to be making an EPS of -0.18 in the current quarter, while forecast for next quarter EPS is 0.1 and it is -0.37 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.22 which is -0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.32 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -164.53% while it is estimated to increase by 3.93% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Leerink Partners on April 25, 2024 offering a Market perform rating for the stock and assigned a target price range of between $12 and $4 to it. Coverage by SVB Securities stated CureVac N.V (CVAC) stock as an Outperform in their note to investors on June 08, 2023, suggesting a price target of $13 for the stock. On January 19, 2023, UBS Upgrade their recommendations, while on January 09, 2023, Jefferies Upgrade their ratings for the stock with a price target of $21. Stock get an Underperform rating from BofA Securities on January 21, 2022.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.